BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 17, 2026
Home » Authors » Cormac Sheridan

Cormac Sheridan

Articles

ARTICLES

ThromboGenics Sets January Launch as FDA Approves Jetrea

Oct. 19, 2012
By Cormac Sheridan
In an eagerly awaited milestone for the company – and for Belgian biotech – the FDA approved ThromboGenics NV's biologic drug Jetrea (ocriplasmin) for treating symptomatic vitreomacular adhesion (VMA).
Read More

Covagen Inks $146M Fynomer Discovery Pact with Mitsubishi

Oct. 18, 2012
By Cormac Sheridan
Covagen AG signed its first drug discovery deal, a pact worth potentially up to €112.25 million (US$146 million) with Mitsubishi Tanabe Pharma Corp. that involves its Fynomer protein scaffold technology.
Read More

Wilex Shares Plunge; Rencarex Disappoints in Phase III Study

Oct. 17, 2012
By Cormac Sheridan
Shares in Wilex AG plunged 60 percent just before the markets closed in Frankfurt, Germany, Tuesday, on news that a protracted Phase III trial of Rencarex (girentuximab) failed to meet the primary endpoint of disease-free survival in patients with clear cell renal carcinoma (ccRCC).
Read More

Spanish Firm Genmedica Adds $15M for Type II Diabetes Trial

Oct. 16, 2012
By Cormac Sheridan
Genmedica Therapeutics SL raised €12 million (US$15.5 million) in a Series B round to move its first-in-class drug candidate, GMC-252, into a Phase I trial in Type II diabetes.
Read More

Spanish Firm Genmedica Adds $15M for Type II Diabetes Trial

Oct. 16, 2012
By Cormac Sheridan
Genmedica Therapeutics SL raised €12 million (US$15.5 million) in a Series B round to move its first-in-class drug candidate, GMC-252, into a Phase I trial in Type II diabetes.
Read More

Pharma-Biotech Tango Continues in Brussels

Oct. 10, 2012
By Cormac Sheridan
BRUSSELS – The smooth sounds of Marvin Gaye's '80s classic 'Sexual Healing' greeted delegates filing in for the opening keynote session at BioPartnering Future Europe meeting at the Square Brussels Meeting Centre Monday.
Read More

Big Pharma Facing Increasing Complexity, More Collaboration

Oct. 10, 2012
By Cormac Sheridan
BRUSSELS, Belgium – Continuing the habit of starting the day's proceedings with unexpected musical choices, the audio-visual technician in charge of the Silver Hall meeting room chose Louis Armstrong's and Ella Fitzgerald's inimitable rendition of "Let's call the whole thing off" to kick off Tuesday's sessions at the BioPartnering Future Europe meeting at the Square Brussels Meeting Centre Tuesday.
Read More

Big Pharma Facing Increasing Complexity, More Collaboration

Oct. 9, 2012
By Cormac Sheridan
BRUSSELS, Belgium – Continuing the habit of starting the day's proceedings with unexpected musical choices, the audio-visual technician in charge of the Silver Hall meeting room chose Louis Armstrong's and Ella Fitzgerald's inimitable rendition of "Let's call the whole thing off" to kick off Tuesday's sessions at the BioPartnering Future Europe meeting at the Square Brussels Meeting Centre Tuesday.
Read More

Pharma-Biotech Tango Continues in Brussels

Oct. 9, 2012
By Cormac Sheridan
BRUSSELS – The smooth sounds of Marvin Gaye's '80s classic 'Sexual Healing' greeted delegates filing in for the opening keynote session at BioPartnering Future Europe meeting at the Square Brussels Meeting Centre Monday.
Read More

Evotec Gets $15M Up Front in Bayer Endometriosis Pact

Oct. 3, 2012
By Cormac Sheridan
Evotec AG is pocketing €12 million (US$15.5 million) up front and could receive up to €580 million more in preclinical, clinical and commercial milestones from a drug discovery alliance focused on endometriosis with Bayer Pharma AG.
Read More
View All Articles by Cormac Sheridan

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 16, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • CAR T and red blood cells

    Viva in vivo! At EHA, in vivo CAR T data continues to impress

    BioWorld
    Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing